LONDON - GlaxoSmithKline PLC (LSE/NYSE: NYSE:GSK) announced today that the European Medicines Agency (EMA) has begun ...
GSK has announced that a pre-filled syringe version of its Shingrix shingles vaccine has been accepted for review by the ...
1d
Hosted on MSNGSK and University of Oxford partner for cancer vaccine researchGSK and the University of Oxford have entered a new research partnership to launch an immuno-prevention programme to explore ...
Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...
EMA accepts for review regulatory application of GSK’s Shingrix new prefilled syringe presentation for prevention of shingles: London, UK Wednesday, January 29, 2025, 13:00 Hrs ...
GSK (GSK) announced that the European Medicines Agency, EMA, has accepted for review the regulatory application of a prefilled syringe ...
London: GSK plc has announced that the European Medicines Agency (EMA) has accepted for review the regulatory application of ...
GSK’s Shingrix new prefilled syringe presentation accepted for review by European Medicines Agency
GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency (EMA) has accepted for review the regulatory application of a prefilled syringe presentation of Shingrix (GSK’s Recombinant ...
GSK has announced that the European Medicines Agency (EMA) has accepted its regulatory application for a prefilled syringe presentation of Shingrix ...
(Sharecast News) - GSK has announced that a pre-filled syringe version of its Shingrix shingles vaccine has been accepted for review by the European Medicines Agency. Shringrix, which has already ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results